Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics

Drug Profile

Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics

Alternative Names: SB-LSD3; SB-LSD4; ZFN Bcl11a; ZFN therapeutics - Sangamo; ZFP nucleases - Sangamo

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics; University of Massachusetts Medical School
  • Class Antineoplastics; Cell therapies; Gene therapies; Stem cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Alpha 1 antitrypsin modulators; CCR5 receptor modulators; Cell replacements; Gene modulators; Gene silencing; Genetic transcription inhibitors; Interleukin 2 receptor modulators; T-cell receptor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity No

Highest Development Phases

  • No development reported Alpha 1-antitrypsin deficiency; Cancer; Down syndrome; HIV infections; Immunodeficiency disorders; Mucopolysaccharidosis I; Mucopolysaccharidosis II

Most Recent Events

  • 07 Feb 2018 Case Western Reserve University and Sangamo Therapeutics plans a phase I trial for HIV infections in USA in 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top